Loading clinical trials...
Loading clinical trials...
The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
GlaxoSmithKline
NCT06712563 · Pulmonary Disease, Chronic Obstructive
NCT07518472 · Pulmonary Disease, Chronic Obstructive (COPD)
NCT06831994 · Asthma Bronchiale, Breast Neoplasms, and more
NCT05730088 · Pulmonary Disease, Chronic Obstructive
NCT02755974 · Pulmonary Disease, Chronic Obstructive
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions